近日，欧洲临床微生物与感染性疾病年会(ECCMID)为庆30周年，在全球范围内评选出30位30岁以下的杰出科研工作者，我院博士后Prasanth Manohar入选，成为中国的唯一获奖者。
For the 30th edition of ECCMID, we would like to highlight 30 outstanding young scientists 30 years of age or younger. ZJE post-doctor, Dr. Prasanth Manohar is one of the awardees and the only one in China.
“
“
Prasanth Manohar博士是一名“90后”，目前在ZJE的Sebastian Leptihn研究员实验室从事博士后研究。于印度韦洛尔理工学院（VIT）取得了博士学位，在博士期间，他获得欧盟INNO Indigo项目支持的“青年科学家奖”和印度政府的“CSIR高级研究奖学金”。他的研究方向是噬菌体生物学、噬菌体治疗和抗生素耐药性。
当被问及为什么来中国从事科研时，他说道，中国是世界上发展最快的经济体之一，掌握着最新的技术。中国有很好的科研环境，为优秀科研工作者提供充足的研究经费，大力支持科研创新项目。此外，他非常喜欢友好的中国人，在海宁的生活非常愉快。
新冠肺炎期间，中国采取了强力并有效的防控措施，因此Prasanth Manohar博士和家人仍在印度未入镜，并将遵照最新指示安排行程。作为从事相近领域研究的科研工作者，谈到本次疫情，他分析说，与“非典”和中东呼吸综合症相比，本次新冠肺炎的死亡率相对较低，但人群传播更快。目前已然成为全球性流行病，医疗体系较薄弱的国家需要更加谨慎，像这样全球性的突发事件一定要依靠政府力量来控制，并且他强调防控比治疗更关键。
Prasanth Manohar博士希望未来能在噬菌体治疗研究方面成为一名出色科学家，他正朝着将噬菌体治疗成为现实而努力，希望解决耐抗生素感染的问题。
关于ECCMID&ECSMID
欧洲临床微生物和感染病学会(ESCMID)成立于1983年，是一个致力于通过促进研究、教育、培训、医疗实践提高感染相关疾病的诊断、治疗和预防水平的非营利组织，是欧洲领先的临床微生物学和感染病学会。30多年来，ESCMID已经成微生物学家和感染病专家职业生涯最有影响力的组成部分，现在世界各地拥有8,500多名个人会员和30,000余名附属成员。
欧洲临床微生物与传染病大会(ECCMID)由欧洲临床微生物和感染病学会(ESCMID)主办，是临床微生物学，感染性疾病和感染控制领域最大最全面、最具影响力的会议，大会将利用最新的技术呈现最科学的教育计划，包括主题演讲、座谈会、海报会议、教育研讨会、专家会面、展览会等多种形式；世界一流的专家将介绍该领域最新的研究结果并和与会者一起进行探讨，本届会议预计将吸引超过13000名来自世界各地的专业人士参会。
“
Dr. Prasanth Manohar is working as a post-doctor in Dr Sebastian Leptihn’s lab in ZJE. He completed his Ph.D in Vellore Institute of Technology (VIT), Vellore, India, during which he was awarded with 'Young scientist award' from INNO Indigo projects, European Union and 'CSIR-Senior Research Fellowship' from Government of India. His research interests are bacteriophage biology, phage therapy and antibiotic resistance.
When asked why came to China for research, he mentioned that China is one of the fastest growing economy in the world withhands-on-use latest technologies, and there are substantial research funding sources available to meet the global needs that eventually supports the scientists to do innovation. Additionally, he loves Chinese people and the life in Haining has been pleasant.
During the COVID-19 outbreak, China carries out strict and effective prevention and control management. Therefore, Dr. Prasanth Manohar and his family still stay in India and waiting for new guideline. As a scientist in close area, Dr. Prasanth tells us that compared with SARS and MERS, covid-19 has lesser fatality rate but rapid transmission within the population. Being pandemic, countries with minimal health aids needs to be more cautious and such global emergency can only be controlled by public support. He stresses that 'prevention is better than cure'.
When it comes to future plan, Dr. Prasanth precisely states that he wants to become one of the reputed scientists in the field of phage therapy and he is working towards bringing phage therapy into a reality to treat antibiotic resistant infections.
About ECCMID&ECSMID
Since its founding in 1983, ESCMID has evolved to become Europe’s leading society in clinical microbiology and infectious diseases with members from all European countries and all continents. For more than 30 years, ESCMID has been an influential component in the professional lives of microbiologists and infectious disease specialists and now reaches more than 8,500 individual and 30,000 affiliated members around the world.
ECCMID held by ECCIM, has become one of the most comprehensive and influential congresses in the field of infection and an exciting networking place bringing together >13,000 colleagues from all over the world. The scientific programme is built by the ECCMID Programme Committee, and independent group of experts representing all disciplines related to clinical microbiology and infectious diseases. The programme is built in two phases, based on submitted session proposals or submitted abstracts.
